Aim: To evaluate the effectiveness and tolerability of exenatide once weekly (EQW) compared with basal insulin (BI) among injectable-drug-naïve patients with type 2 diabetes mellitus (T2DM) who are elderly or have renal impairment (RI).
patients with T2DM are at high risk of the microvascular and macrovascular complications of diabetes, including kidney disease and cardiovascular disease. 2, 3 Long-standing hyperglycaemia is an important risk factor for diabetic nephropathy, and diabetes is the most common cause of chronic kidney disease in the United States. Approximately 20% to 30% of patients with T2DM will develop diabetic nephropathy over time, 4 and a substantial proportion of these patients will progress to kidney failure. 5 The kidneys play an important role in glycaemic control through gluconeogenesis and tubular reabsorption of glucose. 6 Additionally, the kidneys play an important role in the clearance of antihyperglycaemic medications, including glucagon-like protein-1 receptor agonists (GLP-1RAs) and long-acting basal insulin (BI). Renal impairment (RI) alters glycaemic control, placing patients at high risk of both hyperglycaemia and hypoglycaemia. 6 Patients with T2DM
and RI, specifically chronic kidney disease, are at increased risk of cardiovascular complications and death. 7, 8 The treatment goals for patients with T2DM who are elderly or have RI include the management of hyperglycaemia, prevention of diabetes progression, and avoidance of adverse treatment effects, mainly hypoglycaemia. In these populations, complications of hypoglycaemia include increased risks of hospitalization, cardiovascular events and falls or fractures. 5, 8 Elderly patients with T2DM may have RI related to age or T2DM itself, further complicating their treatment options. Intensive treatment for glycaemic control in elderly patients and/or patients with RI may place them at higher risk of hypoglycaemia and its complications. 9 In January 2012, the US Food and Drug Administration approved, Bydureon, a once-weekly form of exenatide (EQW), for the treatment of T2DM. Evidence from clinical trials suggested that EQW improves glucose control compared with twice-daily exenatide and BI, and is associated with lower occurrence of hypoglycaemia compared with BI. [10] [11] [12] Thus, EQW may be a good option for both elderly patients and patients with RI, when an injectable antihyperglycaemic agent is considered. EQW does not require dose titration, as other GLP-1RAs do, and may have other advantages over insulin, such as the prevention of weight gain and the improvement of blood pressure and lipid profiles. 13, 14 Given that elderly patients and patients with RI are typically not well represented in clinical trials, the aim of the present study was to examine the extent to which the benefit of EQW observed in randomized trials translates to these patient groups in a real-world setting.
2 | METHODS
| Data source
The study population was drawn from Optum's Electronic Health 
| Study design and population
We identified injectable-drug-naïve patients with T2DM who initi- 
| Matching
Propensity score matching was implemented in order to achieve balance between EQW and BI initiators with respect to a large number of characteristics. [15] [16] [17] Clinically important variables were identified using univariate cstatistics and were forced into the propensity score model. Other covariates were allowed to enter the model using a stepwise selection based on a univariate P value for entry (P < .2) and a multivariate P value for remaining in model (P < .3). Each EQW initiator was matched to up to two BI initiators using a greedy matching algorithm.
Once an EQW initiator was matched with two BI initiators, the members of the matched set were removed from subsequent matching. 23, 24 Covariates included in the propensity score model were balanced across cohorts, and outcome rates observed among EQW and BI initiators were directly compared.
| Subpopulation definitions
Comparisons between the propensity score-matched EQW and BI initiators were made within 2 subpopulations based on age group (18-64 years and ≥65 years) and renal function (normal renal function defined as eGFR ≥90.00 mL/min/1.73m 2 and RI defined as eGFR <90.00 mL/min/1.73m 2 ).
| Outcome definitions
Change in HbA1c, body weight, blood pressure and lipids (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides) from baseline were the outcomes measuring treatment effectiveness. These outcomes were summarized in standard intervals over the first year after EQW or BI initiation. HbA1c and body weight were summarized quarterly (3-month intervals), and blood pressure and lipid profiles were summarized semi-annually (6-month intervals). The interval value was taken as the mean of values occurring within an interval. If no value was observed in the interval, the value was multiply-imputed (5 imputations) using the fully conditional specification method. 18 Parameter estimates and associated variance (SEs)
were determined within imputed datasets, and pooled (averaged) into a single set of statistics (SAS PROC MIANALYZE) that reflect the uncertainty in parameter estimates within and between all imputations. 25 The occurrence of hypoglycaemia and gastrointestinal symptoms (nausea, vomiting, diarrhoea, constipation), and change in renal function from baseline were measures of treatment tolerability. Hypoglycaemia and gastrointestinal symptoms were identified by using both ICD-9-CM diagnosis codes within structured fields and NLP clinical notes. 21 The ICD-9-CM diagnosis codes used to identify hypoglycaemia were based on a modified algorithm described by Ginde et al. 26 Gastrointestinal symptoms were identified using ICD- Renal function was evaluated using eGFR summarized in standard quarterly intervals over the first year after initiation of EQW or BI treatment. Again, the interval value was taken as the mean of values occurring within an interval or was multiply-imputed if no value was available. Pooled estimates of effect were calculated. Changes in HbA1c, body weight, blood pressure and lipids were calculated as the absolute difference between the measurements taken in the baseline period and in each standard follow-up interval.
| Analysis plan
Distributions of changes across each measure were summarized with the mean, mean of absolute differences, or the frequency of measures that were collapsed into a categorical metric. For each measurement, the estimate and its 95% confidence interval (CI) are presented. Comparing EQW and BI initiators, non-overlapping 95%
CIs indicated a significant difference that was unlikely to be explained by chance.
The frequency and proportion of hypoglycaemia and gastrointestinal symptom events among EQW and BI initiators were tabulated during follow-up. We calculated event incidence rates (IRs) and 95%
CIs, using person-time censored at first event during follow-up.
Cohorts were compared using a relative rate (RR) estimate and its 95% CI. RR estimates with 95% CIs not including the value 1 indicated significant differences in event IR between EQW and BI initiators that were unlikely to be explained by chance.
| Ethics
The study protocol was approved by a central institutional review board and Privacy Board. The study was conducted according to guidelines for Good Pharmacoepidemiology Practice. (Table 1) .
Among patients aged ≥65 years, EQW initiators had greater declines in HbA1c from baseline to all calendar quarter intervals in Outpatient physician visits the first year of follow-up, compared with BI initiators ( Figure 1A ). Figure 2B ). Blood pressure, lipid profiles and eGFR remained stable from baseline to all calendar quarter intervals for both EQW and BI initiators ( Table 2 and Figure 3B ). EQW initiators had a lower risk of hypoglycaemia than BI initiators, which was compatible with a chance finding (RR 0.81, 95%
CI 0.63, 1.05; Table 3 ). Renal function, assessed according to eGFR, remained stable across all four quarters and was similar among EQW and BI initiators in both age groups ( Figure 3A ) and regardless of RI ( Figure 3B ).
| DISCUSSION
We examined the effectiveness and tolerability of EQW compared with BI in patients with T2DM by age group and renal function. While our focus was to assess the effectiveness and tolerability of EQW relative to BI among patients with T2DM who are elderly or BI, basal insulin; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; EQW, exenatide once weekly; HbA1c, glycated haemoglobin; SBP, systolic blood pressure.
a Renal Function was assessed by eGFR; eGFR could not be calculated for 151 patients who did not have race information (18-64 years: EQW (n = 52), BI (n = 89); ≥65 years: EQW (n = 10), BI (n = 24), normal = eGFR ≥90 mL/min/1.73m 2 ; Any RI = eGFR <90 mL/min/1.73m 2 .
b BMI group: underweight/normal = BMI < 24 kg/m 2 ; overweight = 25 kg/m 2 < BMI < 3329 kg/m 2 ; obese = 30 kg/m 2 < BMI < 39 kg/m 2 ; morbidly obese = BMI > 40 kg/m 2 .
c Renal function: normal = eGFR ≥90 mL/min/1.73m 2 ; mild impairment = 60 mL/min/1.73m 2 ≤ eGFR <90 mL/min/1.73m 2 ; moderate/severe impairment = eGFR <60 mL/min/1.73m 2 .
d Moderate and severe impairment populations were combined in this study for matching and analyses; this included patients with both moderate impairment = 30 mL/min/1.73m 2 ≤ eGFR <60 mL/min/1.73m 2 and patients with severe impairment = eGFR <30 mL/min/1.73m 2 measured at baseline.
have RI, comparing young and elderly patients and patients with and without RI provides the real-world evidence that the benefits of EQW relative to BI remain apparent, yet are tempered in elderly patients and patients with RI. Specifically, we observed that EQW ini- 72.7%); fewer patients had moderate RI (EQW: 26.5%; BI: 24.5%) or severe RI (EQW: 0.6%; BI: 2.8%; Table 1 ). The reader should be cautioned that the inferences made in this study are generalizable to patients with mild RI, and possibly mild to moderate RI, only.
Although EQW is excreted through the kidney, no dose alteration has been recommended for patients with mild or moderate RI. 31 EQW is not recommended for patients with severe RI. through the Clinical Laboratory Improvement Amendments (CLIA). 33 The purpose of CLIA is to ensure the accuracy and reliability of laboratory testing. 
